Atossa Therapeutics, Inc.
ATOS
$0.7775
$0.03354.50%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 13.52M | 13.53M | 13.51M | 13.12M | 13.15M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 29.99M | 28.06M | 27.62M | 29.49M | 30.57M |
Operating Income | -29.99M | -28.06M | -27.62M | -29.49M | -30.57M |
Income Before Tax | -28.72M | -26.34M | -25.50M | -26.91M | -25.91M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -28.72 | -26.34 | -25.50 | -26.91 | -25.91 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -28.72M | -26.34M | -25.50M | -26.91M | -25.91M |
EBIT | -29.99M | -28.06M | -27.62M | -29.49M | -30.57M |
EBITDA | -29.97M | -28.04M | -27.60M | -29.46M | -30.55M |
EPS Basic | -0.22 | -0.21 | -0.20 | -0.21 | -0.21 |
Normalized Basic EPS | -0.13 | -0.12 | -0.12 | -0.13 | -0.13 |
EPS Diluted | -0.22 | -0.21 | -0.20 | -0.21 | -0.21 |
Normalized Diluted EPS | -0.13 | -0.12 | -0.12 | -0.13 | -0.13 |
Average Basic Shares Outstanding | 510.72M | 507.29M | 503.44M | 502.12M | 502.14M |
Average Diluted Shares Outstanding | 510.72M | 507.29M | 503.44M | 502.12M | 502.14M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |